Lilly says Jaypirca plus venetoclax regimen cuts progression or death risk 45% in Phase 3 CLL/SLL trial

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • Eli Lilly disclosed Phase 3 BRUIN CLL-322 results showing Jaypirca added to a time-limited venetoclax regimen delayed CLL/SLL worsening versus standard therapy.
  • The data were already generated, with a late-breaking oral presentation scheduled for the 2026 European Hematology Association meeting.
  • The study supports a potential shift in second-line care for patients previously treated with covalent BTK inhibitors, a common prior therapy.
  • Lilly plans regulatory submissions aimed at expanding Jaypirca’s label based on the trial outcome.
  • Safety was broadly consistent with known profiles, with limited added toxicity reported for the combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606140315PR_NEWS_USPR_____DE82213) on June 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.